These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 30017528)

  • 1. Improved management of patients after acute coronary syndrome: using nonalcoholic fatty liver disease fibrosis score and ezetimibe?
    Pitha J
    Int J Cardiol; 2018 Nov; 270():260-261. PubMed ID: 30017528
    [No Abstract]   [Full Text] [Related]  

  • 2. Cardiovascular Risk Reduction in Patients with Nonalcoholic Fatty Liver Disease: The Potential Role of Ezetimibe.
    Simon TG; Corey KE; Chung RT; Giugliano R
    Dig Dis Sci; 2016 Dec; 61(12):3425-3435. PubMed ID: 27714510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ezetimibe improves high fat and cholesterol diet-induced non-alcoholic fatty liver disease in mice.
    Zheng S; Hoos L; Cook J; Tetzloff G; Davis H; van Heek M; Hwa JJ
    Eur J Pharmacol; 2008 Apr; 584(1):118-24. PubMed ID: 18329014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The use of complex tools ezetimibe, hepadyfu fosinopril and correction of blood pressure and endothelial dysfunction in patients with nonalcoholic steatohepatitis and essential hypertension stage II].
    Khukhlina OS; Mandryk OIe; Drozd VIu; Haĭdychuk VS; Kosar LIu
    Wiad Lek; 2014; 67(2 Pt 2):269-72. PubMed ID: 25796845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of ezetimibe on NAFLD.
    Averna M
    Atheroscler Suppl; 2015 Feb; 17():27-34. PubMed ID: 25659874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ezetimibe reduces fatty acid quantity in liver and decreased inflammatory cell infiltration and improved NASH in medaka model.
    Oishi T; Terai S; Kuwashiro S; Fujisawa K; Matsumoto T; Nishina H; Sakaida I
    Biochem Biophys Res Commun; 2012 May; 422(1):22-7. PubMed ID: 22554516
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome.
    Deushi M; Nomura M; Kawakami A; Haraguchi M; Ito M; Okazaki M; Ishii H; Yoshida M
    FEBS Lett; 2007 Dec; 581(29):5664-70. PubMed ID: 18022391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of intestinal cholesterol absorption by ezetimibe is a novel therapeutic target for fatty liver.
    Yamagishi S; Nakamura K; Matsui T; Sato T; Takeuchi M
    Med Hypotheses; 2006; 66(4):844-6. PubMed ID: 16188393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The utility of ezetimibe therapy in nonalcoholic fatty liver disease.
    Jun BG; Cheon GJ
    Korean J Intern Med; 2019 Mar; 34(2):284-285. PubMed ID: 30840809
    [No Abstract]   [Full Text] [Related]  

  • 10. [Efficacy and safety of ezetimibe/simvastatin combination therapy in patients with type 2 diabetes and nonalcoholic fatty liver disease].
    Abel T; Fehér J; Dinya E; Gamal Eldin M; Kovács A
    Orv Hetil; 2009 May; 150(21):989-93. PubMed ID: 19443308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NPC1L1 inhibitor ezetimibe is a reliable therapeutic agent for non-obese patients with nonalcoholic fatty liver disease.
    Enjoji M; Machida K; Kohjima M; Kato M; Kotoh K; Matsunaga K; Nakashima M; Nakamuta M
    Lipids Health Dis; 2010 Mar; 9():29. PubMed ID: 20222991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is ultrasonography-diagnosed nonalcoholic fatty liver disease fibrosis score associated with the Framingham risk score?
    Tanoglu A; Kekilli M
    Eur J Gastroenterol Hepatol; 2015 Jun; 27(6):748-9. PubMed ID: 25919655
    [No Abstract]   [Full Text] [Related]  

  • 13. Hepatic artery resistive index (HARI) and non-alcoholic fatty liver disease (NAFLD) fibrosis score in NAFLD patients: cut-off suggestive of non-alcoholic steatohepatitis (NASH) evolution.
    Tana C; Tana M; Rossi S; Silingardi M; Schiavone C
    J Ultrasound; 2016 Sep; 19(3):183-9. PubMed ID: 27635163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging Targets to Relieve Fat Stress-Induced Liver Diseases: UDCA, Tocotrienol, ω-3 PUFAs, and IgY Targeted NPC1L1 Cholesterol Transporter.
    Cha JY; Park JM; Lee HJ; Bae JS; Han YM; Oh BC; Ko KH; Hahm KB
    Curr Pharm Des; 2017; 23(27):3941-3951. PubMed ID: 28714405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of combined ezetimibe/simvastatin treatment and simvastatin monotherapy in patients with non-alcoholic fatty liver disease.
    Abel T; Fehér J; Dinya E; Eldin MG; Kovács A
    Med Sci Monit; 2009 Dec; 15(12):MS6-11. PubMed ID: 19946244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between nonalcoholic fatty liver disease and coronary artery disease complexity in patients with acute coronary syndrome: a pilot study.
    Agaç MT; Korkmaz L; Cavusoglu G; Karadeniz AG; Agaç S; Bektas H; Erkan H; Varol MO; Vatan MB; Acar Z; Mentese U; Celik S
    Angiology; 2013 Nov; 64(8):604-8. PubMed ID: 23439214
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PNPLA3 I148M variant in nonalcoholic fatty liver disease: demographic and ethnic characteristics and the role of the variant in nonalcoholic fatty liver fibrosis.
    Chen LZ; Xin YN; Geng N; Jiang M; Zhang DD; Xuan SY
    World J Gastroenterol; 2015 Jan; 21(3):794-802. PubMed ID: 25624712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New scoring system combining the FIB-4 index and cytokeratin-18 fragments for predicting steatohepatitis and liver fibrosis in patients with nonalcoholic fatty liver disease.
    Tada T; Kumada T; Toyoda H; Saibara T; Ono M; Kage M
    Biomarkers; 2018; 23(4):328-334. PubMed ID: 29308929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ezetimibe plus moderate-dose simvastatin after acute coronary syndrome: what are we IMPROVEing on?
    DiNicolantonio JJ; Chatterjee S; Lavie CJ; Bangalore S; O'Keefe JH
    Am J Med; 2015 Aug; 128(8):914.e1-4. PubMed ID: 25731133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unexpected beneficial effect in the use of ezetimibe in non-alcoholic fatty liver disease.
    Hughes EA; Tracey I; Singhal S; Patel J
    Med Hypotheses; 2006; 67(6):1463-4. PubMed ID: 16831521
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.